The All India Institute of Medical Sciences (AIIMS), Bhopal, has signed a Memorandum of Understanding (MoU) with the Council of Scientific and Industrial Research and Center for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad, to improve the diagnostic and research capabilities. initiatives against sickle cell disease and related genetic diseases. This collaboration marks an important step in addressing the challenges of sickle cell disease, particularly in central India.

Prof. (Dr.) Ajai Singh, Executive Director, AIIMS Bhopal, highlighted the importance of this partnership, saying, “Our collaboration with CSIR-CCMB is an important step towards improving the diagnostic capabilities of sickle cell disease. .

The introduction of this PCR-based test will allow us to offer accurate diagnostics, particularly in underserved communities, significantly improving patient care. » He further noted that the test is currently in the initial validation phase and will be compared to other government-approved tests. tests.

A key aspect of this partnership is the implementation of a PCR-based molecular diagnostic test developed by CSIR-CCMB, which will be operational at AIIMS Bhopal. This advanced diagnostic tool aims to provide patients with rapid and accurate diagnostic capabilities, thereby leading to better management of sickle cell disease.

Dr Giriraj Chandak, Head of Sickle Cell Disease Mission at CSIR-CCMB, said, “This MoU is an important milestone in our mission to bring scientific advancements to those who need it most. Through this partnership, the PCR-based test we developed can now benefit countless patients, advancing diagnostic and research capabilities in the field of sickle cell disease.

Beyond the implementation of the PCR-based test, this collaboration will promote joint research projects focused on sickle cell disease and genetic health. The partnership aims to promote advances in genetic research, improve clinical understanding and contribute significantly to public health.